Discounted Cash Flow
Immunocore Holdings Plc. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2018 | $23.7m | $-88.2m | $-20.1m | -372.8% | $-3.32 |
| 2019 | $25.7m (8.5%) | $-126.2m (-43.1%) | $-105.5m (-424.3%) | -491.6% (-31.9%) | $-4.66 (-40.4%) |
| 2020 | $30.1m (17.3%) | $-87.4m (30.8%) | $-63.6m (39.6%) | -290.1% (41.0%) | $-2.79 (40.1%) |
| 2021 | $26.5m (-11.9%) | $-140.9m (-61.3%) | $-97.1m (-52.6%) | -531.4% (-83.2%) | $-3.10 (-11.1%) |
| 2022 | $143.7m (442.0%) | $-44.1m (68.7%) | $-27.7m (71.5%) | -30.7% (94.2%) | $-0.90 (71.0%) |
| 2023 | $238.7m (66.1%) | $-55.3m (-25.2%) | $-2.5m (91.0%) | -23.2% (24.6%) | $-1.13 (-25.6%) |
| 2024 | $310.2m (29.9%) | $-51.1m (7.6%) | $20.9m (940.6%) | -16.5% (28.9%) | $-1.02 (9.7%) |
| 2025 | $400.0m (29.0%) | $-35.5m (30.5%) | $-15.1m (-172.1%) | -8.9% (46.1%) | $-0.71 (30.4%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.